Published in Medical Letter on the CDC and FDA, January 20th, 2008
Patrick Fourteau, Chief Executive Officer of Sciele Pharma, said, "We are excited about this approval by the FDA for the new Sular formulation. This validates our product development and regulatory capabilities, as we have become a fully integrated...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.